BIOCRYST PHARMACEUTICALS INC

Key metrics

Financial performance

Over the last 9 fiscal years BIOCRYST PHARMACEUTICALS INC's revenue grew from $26.35M to $874.84M, a compound annual growth rate of 47.6%. Net profit margin expanded from -209.3% to 30.2% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (1,935 filings)

Recent press releases

• BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting2026-05-27

  Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO ® (berotralstat), the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older, and one abstract featuring clinical trial outcomes with navenibart, a long-acting, monoclonal antibody plasma kallikrein inhibitor being investigated for prophylaxis to prevent attacks of HAE.

• BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 20262026-05-13

  Studies highlight the significant healthcare and quality-of-life burden associated with hereditary angioedema (HAE) in pediatric patients and their caregivers, demonstrating persistent unmet needs and the importance of optimized disease management to reduce healthcare utilization. Underscoring the role of outcomes research in rare diseases, the research draws on large U.S. insurance claims data and mixed-methods caregiver insights to examine both healthcare resource utilization and the day-to-day impact of pediatric HAE on caregivers.

• BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update2026-05-06

  — Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) —

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2026-05-05

  The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.

• BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema2026-05-04

  — BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe —

Similar companies

The largest companies sharing BIOCRYST PHARMACEUTICALS INC's SEC industry classification (biological products, (no diagnostic substances)).